A newly described cutaneous reaction at sites of insulin pump use in a child with Type 1 diabetes

Victoria A Perez; Sameera Husain; Cynthia M Magro; Mark A Strom; Kristen M Williams; Laura E Levin

doi:10.1111/pde.14438

A newly described cutaneous reaction at sites of insulin pump use in a child with Type 1 diabetes

Pediatr Dermatol. 2021 Jan;38(1):239-241. doi: 10.1111/pde.14438. Epub 2020 Nov 10.

Authors

Victoria A Perez¹, Sameera Husain², Cynthia M Magro³, Mark A Strom⁴, Kristen M Williams⁵, Laura E Levin⁴

Affiliations

¹ Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
² Division of Dermatopathology, Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.
³ Department of Pathology & Laboratory Medicine, Cornell University, New York, NY, USA.
⁴ Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.
⁵ Division of Pediatric Endocrinology, Columbia University Irving Medical Center, New York, NY, USA.

PMID: 33169884
DOI: 10.1111/pde.14438

Abstract

Continuous subcutaneous insulin infusion (CSII), or insulin pumps, with or without continuous glucose monitoring (CGM) devices have become the standard of care for patients with type 1 diabetes. While increasingly popular, a wide range of reported skin reactions to CSII and CGM devices was found. We present this case of a pyogenic granuloma-like neutrophilic and granulomatous response to an insulin pump to increase awareness of a previously uncharacterized cutaneous adverse reaction at insulin pump infusion sites.

Keywords: Type 1 diabetes; granulomatous; insulin pump; nodules.

Publication types

Case Reports

MeSH terms

Blood Glucose
Blood Glucose Self-Monitoring
Child
Diabetes Mellitus, Type 1* / drug therapy
Humans
Hypoglycemic Agents / adverse effects
Insulin Infusion Systems

Substances

Blood Glucose
Hypoglycemic Agents